Foresite Capital Management IV, LLC
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1704132
West Hollywood, CA
Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$16,056,003
-$8,580,278 QoQ
Shares Held
800,399
0.0% QoQ
Ownership
3.43%
of shares outstanding
% of Portfolio
6.77%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Foresite Capital Management IV, LLC holds $237,082,218 across 8 Biotechnology names. LYEL ranks #4 (6.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PHVS |
Pharvaris N.V.
|
4,778,581 | $134,994,913 | |
| 2 | CYTK |
Cytokinetics Inc
|
503,295 | $33,172,173 | |
| 3 | EIKN |
Eikon Therapeutics, Inc.
|
1,943,682 | $20,564,155 | |
| 4 | LYEL |
Lyell Immunopharma, Inc.
This page
|
800,399 | $16,056,003 | |
| 5 | RLAY |
Relay Therapeutics, Inc.
|
1,000,000 | $9,950,000 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
160,000 | $9,304,000 | |
| 7 | ALEC |
Alector, Inc.
|
3,887,200 | $8,357,480 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
156,901 | $4,683,494 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,056,003 | 800,399 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $24,636,281 | 800,399 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $12,998,479 | 800,399 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,075,527 | 800,399 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||